Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks

Executive Summary

Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.

You may also be interested in...



AAM Unveils ‘Long Overdue’ Membership Roles

The US Association for Accessible Medicines has for the first time appointed two member-focused roles within its organization, as long-serving policy executive Christine Simmon was also handed a promotion.

Generic Industry’s Future May Include A Role In The Gene Therapy Space

Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.

ANDA Submissions Drop To Start FY2021

First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.

Related Content

Topics

UsernamePublicRestriction

Register

PS143243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel